Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Delta-2-Albomycin A1 is a natural antibiotic belonging to the albomycin family, produced by Gram-positive Actinomyces subtropicus bacteria. It is an iron(III) complexed siderophore-antibiotic conjugate, classified as a "Trojan horse" antibiotic. The molecule consists of an iron-chelating hydroxamate-type siderophore linked to an antibiotic warhead. Bacteria recognize and import the compound via their iron uptake systems; once inside, the antibiotic moiety inhibits essential bacterial processes, leading to bacteriostatic effects. Delta-2-Albomycin A1 has demonstrated potent in vitro activity against both Gram-negative and Gram-positive pathogens—including methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae—surpassing standard antibiotics like ciprofloxacin, vancomycin, and penicillin in potency. However, it remains experimental due to synthesis challenges and lack of commercial development[5][4][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on delta-2-albomycin a1.